期刊文献+

ID4基因甲基化定量PCR检测在急性白血病中的临床意义 被引量:6

Clinical Significance of ID4 Methylation Detection by Quantitative Methylation-Specific PCR in Acute Leukemia
在线阅读 下载PDF
导出
摘要 尽管治疗的进步极大地改善了急性白血病患者的预后和生存,但时至今日多数类型的急性白血病没有特异性的生物标记,因此对于多数白血病患者,影响生存的复发这一重要因素缺少有效的预警机制。ID4基因启动子区甲基化广泛发生于各类型急性白血病。本研究在前期建立的甲基化定量PCR体系的基础上,用该方法检测患者骨髓样本,探讨ID4甲基化定量指标(percentage of methylated reference,PMR)的临床意义。采集我院门诊及住院确诊的初治、完全缓解、复发3个阶段的急性白血病患者骨髓样本及正常对照者骨髓样本。应用ID4甲基化定量PCR体系对样本进行检测。按初治、完全缓解、复发分组比较PMR值。比较相同病例不同疾病状态的PMR的动态变化。结果表明,初治组PMR最高,其次为复发组,而完全缓解组最低。初治组PMR与完全缓解组比较存在统计学差异。4例随访病例的PMR值波动与病情变化一致。在1例复发病例中,PMR升高早于骨髓细胞学检查确认复发1.7个月。结论:本研究通过ID4基因启动子区甲基定量检测的方法初步验证:甲基化水平的量化指标PMR值与急性白血病患者肿瘤细胞负荷关系密切。PMR动态监测波动与疾病变化一致,可能具有预测复发的作用,但ID4甲基化定量指标的临床价值还有待进一步研究证据的支持。 The advances of treatment improved the prognosis of the patients with acute leukemia (AL) in the last decade, but the lack of general biomarker for predicting relapse in AL, which is one of the most important factors influ- encing the survival and prognosis. DNA methylation of ID4 gene promoter occurred frequently in patients with AL and was found to be highly related to the tumor progression. Based on the previous work of the setup of methylation-specific quantitative PCR system for ID4 gene, this study was designed to investigate the relation between the quantitative indicator of methylation density, percentage of methylation reference(PMR) value, and different disease status of AL. PMR of ID4 was detected by MS-PCR in bone marrow (BM) samples of 17 healthy persons and 54 AL patients in the status of newy diagnosis, complete remission and disease relapse. The results showed that at different disease status, PMR val- ue in newly diagnosed group was significantly lower than that in complete remission group (P = 0. 031 ). Among serial samples, PMR value remained very low at the status of patients with continuous complete remission ( 〈 1.5%0), and increased along with the accumulation of tumor cells at relapse. In 1 relapse case, the abnormal rise of PMR value occurred prior to morphological relapse. PMR value seemed to be related to body tumor cell load. It is concluded that the quantitative indicator of methylation density and PMR value may reflect the change of tumor cell load in acute leukemia patients. Dynamic monitoring of PMR maybe predict leukemia relapse.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2014年第3期675-680,共6页 Journal of Experimental Hematology
基金 解放军总医院临床科研扶持基金(2012FC-TSYS-2002) 国家自然科学基金项目(30901187)
关键词 ID4基因 DNA甲基化 甲基化定量PCR 急性白血病 ID4 gene DNA methylation quantitive methylation-specific PCR acute leukemia
  • 相关文献

参考文献19

  • 1Matsumoto K, Yamamoto W, Ogusa E, et l. Prognostic index for re- lapsed acute leukemia after allogeneic stem cell transplantation. Leuk Lymphoma, 2014 ( Epub ahead of print).
  • 2Della PMG, Alessandrino EP, Bacigalupo A, et al. Predictive fac- tors for the outcome of allogeneic transplantation in patients with my- elodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Blood, 2014 ; 123 ( 15 ) :2333 -42.
  • 3Rossi G, Minervini MM, Melillo L, et al. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a com- parison between multiparameter flow cytometry and Wilm's tumor 1 levels. Ann Hematol, 2014( Epub ahead of print).
  • 4Zhao Y, Luo Y, Shi J, et al. Short-Time Second-Generation Tyro- sine Kinase Inhibitors Combined With Stem Cell Transplantation in Patients With Imatinib-Refraetory Chronic Myeloid Leukemia in Ad- vanced Phases. Am J Med Sci, 2014(Epub ahead of print).
  • 5Buffart TE, Overmeer RM, Steenbergen RD, et al. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer, 2008 ; 99( 11 ) : 1802 - 1807.
  • 6Mehta TK, Hoque MO, Ugarte R, et al. Quantitative detection of promoter hypermethylation as a biomarker of acute kidney injury dur- ing transplantation. Transplant Proc, 2006 ; 38 ( 10 ) : 3420 - 3426.
  • 7Chuang CK, Chu DC, Tzou RD, et al. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer De- tect Prey, 2007; 31(1): 59-63.
  • 8Gallagher WM, Bergin OE, Rafferty M, et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transeriptomic studies. Carcinogenesis, 2005; 26 ( 11 ) : 1856 - 1867.
  • 9赵瑜,王全顺,窦丽萍,薄剑,李红华,靖?,于力.急性白血病Id4基因启动子区甲基化状态研究[J].中国实验血液学杂志,2007,15(6):1156-1160. 被引量:12
  • 10赵瑜,李红华,窦立萍,靖彧,王全顺,于力.DNA抑制因子4作为急性淋巴细胞白血病临床复发前报告因子的可行性初探[J].中国实验血液学杂志,2008,16(5):990-992. 被引量:3

二级参考文献45

  • 1LiYu,ChunhuiLiu,JeffVandeusen,BrianBecknell,ZunyanDai,Yue-ZhongWu,AparnaRaval,Te-HuiLiu,WeiDing,CharleneMao,ShujunLiu,LauraTSmith,StephenLee,LauraRassenti,GuidoMarcucci,JohnByrd,MichaelACaligiuri,ChristophPlass.Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia[J].中国生物学文摘,2005,19(4):109-118. 被引量:80
  • 2赵瑜,于力,王全顺,李红华,薄剑,王书红,靳海杰,楼方定.Id4基因甲基化在急性白血病微量残留病检测中的意义[J].中华血液学杂志,2006,27(5):298-301. 被引量:18
  • 3赵瑜,于力,王全顺,李红华,薄剑,窦丽萍.DNA结合抑制因子4基因甲基化状态检测在急性白血病中的意义[J].中华内科杂志,2006,45(7):576-578. 被引量:24
  • 4王建祥.急性髓系白血病的化疗[A]..第八次全国血液学学术会议论文汇编[C].北京,2004.第31页.
  • 5Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.Expert Opin Biol Ther, 2001; 1: 893 -901.
  • 6Leopold LH, Berger MS, Feingold J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma, 2002; 2 ( Suppl 1 ): S29- S34.
  • 7Tsimberidou A, Estey F, Cortes J, et al. Gemtuzumab, fiudarabine, cytarbine and cyclosporine in patients with newly newly diagnosed acute myelogenous leukemin or high-risk myelodysplastic syndrome. Cancer, 2003; 97:1481 - 1487.
  • 8LoCoco F, Cimino G, Breccia M, et al. Gentuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 2004; 104: 1995 - 1999.
  • 9Lundin J, Kimby E, Bjorkholm M, et al. Phase Ⅱ trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campth1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2002; 100: 768 - 773.
  • 10Hillmen P. Advancing therapy for chronic lymphocytic leukemia -the role of rituximab. Semin Oncol, 2004; 31 (Suppl 2): 22 -26.

共引文献58

同被引文献46

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部